Cost of revenue · 2023–2025
Iovance Biotherapeutics cost of revenue
$173M+85.7% · FY2025
Iovance Biotherapeutics (IOVA) reported $173M in cost of revenue for fiscal 2025, +85.7% year on year.
Cost of revenue — Cost of revenue is the direct cost of producing what the company sold — materials, manufacturing and the labour tied to delivery. It excludes sales, marketing and administration. Revenue minus this figure is gross profit.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2023–2025 compound annual growth +1,194.8%
Cost of revenue at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Iovance Biotherapeutics cost of revenue |url=https://companiesranked.com/en/company/iovance-biotherapeutics/cost-of-revenue |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Iovance Biotherapeutics cost of revenue. CompaniesRanked. https://companiesranked.com/en/company/iovance-biotherapeutics/cost-of-revenueBibTeX
@misc{companiesranked-en-company-iovance-biotherapeutics-cost-of-revenue-2026,
author = {{CompaniesRanked}},
title = {{Iovance Biotherapeutics cost of revenue}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/iovance-biotherapeutics/cost-of-revenue}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001104659-26-018899 · February 24, 2026
{{cite web |title=Iovance Biotherapeutics cost of revenue — 10-K (0001104659-26-018899) |url=https://www.sec.gov/Archives/edgar/data/1425205/000110465926018899/iova-20251231x10k.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.